O	0	9	Targeting	Target	VBG	B-VP
O	10	14	wide	wide	JJ	B-NP
O	14	15	-	-	HYPH	I-NP
O	15	20	range	range	NN	I-NP
O	21	30	oncogenic	oncogenic	JJ	I-NP
O	31	45	transformation	transformation	NN	I-NP
O	46	49	via	via	IN	B-PP
O	50	57	PU24FCl	PU24FCl	NN	B-NP
O	57	58	,	,	,	O
O	59	60	a	a	DT	B-NP
O	61	69	specific	specific	JJ	I-NP
O	70	79	inhibitor	inhibitor	NN	I-NP
O	80	82	of	of	IN	B-PP
B-Cancer	83	88	tumor	tumor	NN	B-NP
O	89	94	Hsp90	Hsp90	NN	I-NP
O	94	95	.	.	.	O

O	97	103	Agents	Agent	NNS	B-NP
O	104	108	that	that	WDT	B-NP
O	109	116	inhibit	inhibit	VBP	B-VP
O	117	122	Hsp90	Hsp90	NN	B-NP
O	123	131	function	function	NN	I-NP
O	132	136	hold	hold	VBP	B-VP
O	137	148	significant	significant	JJ	B-NP
O	149	156	promise	promise	NN	I-NP
O	157	159	in	in	IN	B-PP
B-Cancer	160	166	cancer	cancer	NN	B-NP
O	167	174	therapy	therapy	NN	I-NP
O	174	175	.	.	.	O

O	176	180	Here	Here	RB	B-ADVP
O	181	183	we	we	PRP	B-NP
O	184	191	present	present	VBP	B-VP
O	192	199	PU24FCl	PU24FCl	NN	B-NP
O	199	200	,	,	,	O
O	201	202	a	a	DT	B-NP
O	203	217	representative	representative	NN	I-NP
O	218	220	of	of	IN	B-PP
O	221	224	the	the	DT	B-NP
O	225	230	first	first	JJ	I-NP
O	231	236	class	class	NN	I-NP
O	237	239	of	of	IN	B-PP
O	240	248	designed	design	VBN	B-NP
O	249	254	Hsp90	Hsp90	NN	I-NP
O	255	265	inhibitors	inhibitor	NNS	I-NP
O	265	266	.	.	.	O

O	267	269	By	By	IN	B-PP
O	270	282	specifically	specifically	RB	B-ADVP
O	283	286	and	and	CC	I-ADVP
O	287	295	potently	potently	RB	I-ADVP
O	296	306	inhibiting	inhibit	VBG	B-VP
B-Cancer	307	312	tumor	tumor	NN	B-NP
O	313	318	Hsp90	Hsp90	NN	I-NP
O	318	319	,	,	,	O
O	320	327	PU24FCl	PU24FCl	NN	B-NP
O	328	336	exhibits	exhibit	VBZ	B-VP
O	337	341	wide	wide	JJ	B-ADJP
O	341	342	-	-	HYPH	O
O	342	349	ranging	range	VBG	B-VP
O	350	354	anti	anti	AFX	B-NP
O	354	355	-	-	HYPH	I-NP
B-Cancer	355	361	cancer	cancer	NN	I-NP
O	362	372	activities	activity	NNS	I-NP
O	373	377	that	that	WDT	B-NP
O	378	383	occur	occur	VBP	B-VP
O	384	386	at	at	IN	B-PP
O	387	394	similar	similar	JJ	B-NP
O	395	400	doses	dose	NNS	I-NP
O	401	403	in	in	IN	B-PP
O	404	407	all	all	DT	B-NP
O	408	414	tested	test	VBN	I-NP
B-Cancer	415	420	tumor	tumor	NN	I-NP
O	421	426	types	type	NNS	I-NP
O	426	427	.	.	.	O

O	428	434	Normal	Normal	JJ	B-NP
B-Cell	435	440	cells	cell	NNS	I-NP
O	441	444	are	be	VBP	B-VP
O	445	447	10	10	CD	B-NP
O	447	448	-	-	HYPH	B-ADJP
O	449	451	to	to	TO	B-PP
O	452	454	50	50	CD	B-NP
O	454	455	-	-	HYPH	O
O	455	459	fold	fold	RB	B-ADJP
O	460	464	more	more	RBR	I-ADJP
O	465	474	resistant	resistant	JJ	I-ADJP
O	475	477	to	to	TO	B-PP
O	478	483	these	these	DT	B-NP
O	484	491	effects	effect	NNS	I-NP
O	491	492	.	.	.	O

O	493	496	Its	Its	PRP$	B-NP
O	497	502	Hsp90	Hsp90	NN	I-NP
O	503	513	inhibition	inhibition	NN	I-NP
O	514	521	results	result	VBZ	B-VP
O	522	524	in	in	IN	B-PP
O	525	533	multiple	multiple	JJ	B-NP
O	534	538	anti	anti	AFX	I-NP
O	538	539	-	-	HYPH	I-NP
B-Cancer	539	544	tumor	tumor	NN	I-NP
O	544	545	-	-	HYPH	I-NP
O	545	553	specific	specific	JJ	I-NP
O	554	561	effects	effect	NNS	I-NP
O	561	562	,	,	,	O
O	563	567	such	such	JJ	B-PP
O	568	570	as	as	IN	I-PP
O	571	582	degradation	degradation	NN	B-NP
O	583	585	of	of	IN	B-PP
O	586	591	Hsp90	Hsp90	NN	B-NP
O	591	592	-	-	HYPH	B-NP
O	592	598	client	client	NN	I-NP
O	599	607	proteins	protein	NNS	I-NP
O	608	616	involved	involve	VBN	B-VP
O	617	619	in	in	IN	B-PP
B-Cell	620	624	cell	cell	NN	B-NP
O	625	631	growth	growth	NN	I-NP
O	631	632	,	,	,	O
O	633	641	survival	survival	NN	B-NP
O	641	642	,	,	,	O
O	643	646	and	and	CC	O
O	647	655	specific	specific	JJ	B-NP
O	656	670	transformation	transformation	NN	I-NP
O	670	671	,	,	,	O
O	672	682	inhibition	inhibition	NN	B-NP
O	683	685	of	of	IN	B-PP
B-Cell	686	692	cancer	cancer	NN	B-NP
I-Cell	693	697	cell	cell	NN	I-NP
O	698	704	growth	growth	NN	I-NP
O	704	705	,	,	,	O
O	706	711	delay	delay	NN	B-NP
O	712	714	of	of	IN	B-PP
B-Cell	715	719	cell	cell	NN	B-NP
O	720	725	cycle	cycle	NN	I-NP
O	726	737	progression	progression	NN	I-NP
O	737	738	,	,	,	O
O	739	748	induction	induction	NN	B-NP
O	749	751	of	of	IN	B-PP
O	752	765	morphological	morphological	JJ	B-NP
O	766	769	and	and	CC	I-NP
O	770	780	functional	functional	JJ	I-NP
O	781	788	changes	change	NNS	I-NP
O	788	789	,	,	,	O
O	790	793	and	and	CC	O
O	794	803	apoptosis	apoptosis	NN	B-NP
O	803	804	.	.	.	O

O	805	807	In	In	IN	B-PP
O	808	819	concordance	concordance	NN	B-NP
O	820	824	with	with	IN	B-PP
O	825	828	its	its	PRP$	B-NP
O	829	835	higher	high	JJR	I-NP
O	836	844	affinity	affinity	NN	I-NP
O	845	848	for	for	IN	B-PP
B-Cancer	849	854	tumor	tumor	NN	B-NP
O	855	860	Hsp90	Hsp90	NN	I-NP
O	860	861	,	,	,	O
O	862	864	in	in	FW	B-NP
O	865	869	vivo	vivo	FW	I-NP
O	870	877	PU24FCl	PU24FCl	NN	I-NP
O	878	889	accumulates	accumulate	VBZ	B-VP
O	890	892	in	in	IN	B-PP
B-Cancer	893	899	tumors	tumor	NNS	B-NP
O	900	905	while	while	IN	B-SBAR
O	906	911	being	be	VBG	B-VP
O	912	919	rapidly	rapidly	RB	I-VP
O	920	927	cleared	clear	VBN	I-VP
O	928	932	from	from	IN	B-PP
O	933	939	normal	normal	JJ	B-NP
B-Tissue	940	946	tissue	tissue	NN	I-NP
O	946	947	.	.	.	O

O	948	962	Concentrations	Concentration	NNS	B-NP
O	963	971	achieved	achieve	VBD	B-VP
O	972	974	in	in	FW	B-ADVP
O	975	979	vivo	vivo	FW	I-ADVP
O	980	982	in	in	IN	B-PP
B-Cancer	983	989	tumors	tumor	NNS	B-NP
O	990	994	lead	lead	VBP	B-VP
O	995	997	to	to	TO	B-PP
O	998	1004	single	single	JJ	B-NP
O	1004	1005	-	-	HYPH	I-NP
O	1005	1010	agent	agent	NN	I-NP
O	1011	1015	anti	anti	AFX	O
O	1015	1016	-	-	HYPH	O
B-Cancer	1016	1021	tumor	tumor	NN	B-NP
O	1022	1030	activity	activity	NN	I-NP
O	1031	1033	at	at	IN	B-PP
O	1034	1037	non	non	AFX	B-NP
O	1037	1038	-	-	HYPH	I-NP
O	1038	1043	toxic	toxic	JJ	I-NP
O	1044	1049	doses	dose	NNS	I-NP
O	1049	1050	.	.	.	O

